学术环境中的药物研发：发挥自身优势。
Drug discovery in an academic setting: playing to the strengths.
作者信息
Huryn Donna M
机构信息
Department of Pharmaceutical Sciences, University of Pittsburgh , 712 Salk Hall, 3501 Terrace Street, Pittsburgh, Pennsylvania 15261, United States.
出版信息
ACS Med Chem Lett. 2013 Jan 17;4(3):313-5. doi: 10.1021/ml400012g. eCollection 2013 Mar 14.
Abstract
Drug discovery and medicinal chemistry initiatives in academia provide an opportunity to create a unique environment that is distinct from the traditional industrial model. Two characteristics of a university setting that are not usually associated with pharma are the ability to pursue high-risk projects and a depth of expertise, infrastructure, and capabilities in focused areas. Encouraging, supporting, and fostering drug discovery efforts that take advantage of these and other distinguishing characteristics of an academic setting can lead to novel and innovative therapies that might not be discovered otherwise.
摘要
学术界的药物研发和药物化学项目提供了一个机会，来创建一个有别于传统产业模式的独特环境。大学环境的两个通常与制药行业无关的特点是能够开展高风险项目，以及在特定领域拥有深厚的专业知识、基础设施和能力。鼓励、支持并促进利用学术环境的这些及其他显著特征的药物研发工作，可能会带来否则可能无法发现的新颖创新疗法。
相似文献
1
Drug discovery in an academic setting: playing to the strengths.学术环境中的药物研发：发挥自身优势。
ACS Med Chem Lett. 2013 Jan 17;4(3):313-5. doi: 10.1021/ml400012g. eCollection 2013 Mar 14.
2
Guidelines, editors, pharma and the biological paradigm shift.指南、编辑、制药行业与生物学范式转变
Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.
3
Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.在桑福德·伯纳姆医学研究所与学术界以及制药/生物技术合作伙伴开展临床前药物发现的合作前期工作：基础设施、能力与运营模式
Comb Chem High Throughput Screen. 2014 Mar;17(3):272-89. doi: 10.2174/1386207317666140109124735.
4
Contributions of academic laboratories to the discovery and development of chemical biology tools.学术实验室对化学生物学工具的发现和开发的贡献。
J Med Chem. 2013 Sep 26;56(18):7161-76. doi: 10.1021/jm400132d. Epub 2013 May 31.
5
Academic-Pharma drug discovery alliances: seeking ways to eliminate the valley of death.学术-制药药物研发联盟：探寻消除死亡谷的方法。
Future Med Chem. 2015;7(14):1891-9. doi: 10.4155/fmc.15.111. Epub 2015 Sep 22.
6
The reproducibility issue and preclinical academic drug discovery: educational and institutional initiatives fostering translation success.重现性问题与临床前学术药物研发：促进转化成功的教育与机构举措。
Expert Opin Drug Discov. 2016 Sep;11(9):835-42. doi: 10.1080/17460441.2016.1212014. Epub 2016 Jul 25.
7
The Drug Discovery Portal: a resource to enhance drug discovery from academia.药物发现门户：一个增强学术界药物发现的资源。
Drug Discov Today. 2010 Aug;15(15-16):679-83. doi: 10.1016/j.drudis.2010.06.003. Epub 2010 Jun 12.
8
On the bridge over the translational valley of death: interview with Per I Arvidsson.跨越死亡之谷的桥梁：对佩尔·I·阿维德松的访谈
Future Sci OA. 2017 Apr 10;3(2):FSO183. doi: 10.4155/fsoa-2017-0019. eCollection 2017 Jun.
9
The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.美国学术界药物发现与开发的现状：工业界与学术界合作对药物发现与开发的影响。
Clin Transl Sci. 2018 Nov;11(6):597-606. doi: 10.1111/cts.12577. Epub 2018 Jul 30.
10
Drug discovery in academia.学术界的药物研发
Am J Physiol Cell Physiol. 2004 Mar;286(3):C465-74. doi: 10.1152/ajpcell.00397.2003.
引用本文的文献
1
The Resurrection of Phenotypic Drug Discovery.表型药物发现的复兴
ACS Med Chem Lett. 2020 Mar 6;11(10):1820-1828. doi: 10.1021/acsmedchemlett.0c00006. eCollection 2020 Oct 8.
2
A Medicinal Chemist's Perspective on Transitioning from Industry to Academic Drug Discovery.一位药物化学家对从制药行业转向学术性药物研发的看法。
ACS Med Chem Lett. 2019 Apr 15;10(5):687-689. doi: 10.1021/acsmedchemlett.9b00107. eCollection 2019 May 9.
3
The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.美国学术界药物发现与开发的现状：工业界与学术界合作对药物发现与开发的影响。
Clin Transl Sci. 2018 Nov;11(6):597-606. doi: 10.1111/cts.12577. Epub 2018 Jul 30.
4
Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective.财团在开发针对再次出现的病毒感染的医学应对措施中的关键作用：美国视角。
Future Virol. 2016 Mar;11(3):187-195. doi: 10.2217/fvl-2015-0011. Epub 2016 Feb 29.
5
Mitigating risk in academic preclinical drug discovery.减轻临床前学术药物研发中的风险。
Nat Rev Drug Discov. 2015 Apr;14(4):279-94. doi: 10.1038/nrd4578.
6
Academic medical product development: an emerging alliance of technology transfer organizations and the CTSA.学术性医疗产品开发：技术转移组织与临床与转化科学奖联盟的新兴合作关系
Clin Transl Sci. 2014 Dec;7(6):456-64. doi: 10.1111/cts.12175. Epub 2014 Jun 19.
7
Contributions of academic laboratories to the discovery and development of chemical biology tools.学术实验室对化学生物学工具的发现和开发的贡献。
J Med Chem. 2013 Sep 26;56(18):7161-76. doi: 10.1021/jm400132d. Epub 2013 May 31.
本文引用的文献
1
Future horizons in drug discovery research.
ACS Med Chem Lett. 2012 Jan 20;3(2):80-2. doi: 10.1021/ml3000116. eCollection 2012 Feb 9.
2
Challenges for academic drug discovery.学术性药物研发面临的挑战。
Angew Chem Int Ed Engl. 2012 Nov 19;51(47):11680-4. doi: 10.1002/anie.201204625. Epub 2012 Oct 24.
3
Growing PAINS in academic drug discovery.学术药物研发中的日益增长的困境。
Future Med Chem. 2011 May;3(7):797-801. doi: 10.4155/fmc.11.44.
4
US academic drug discovery.美国学术性药物研发
Nat Rev Drug Discov. 2011 Jun;10(6):409-10. doi: 10.1038/nrd3462.
5
Observations on screening-based research and some concerning trends in the literature.基于筛查的研究观察及文献中一些令人关注的趋势。
Future Med Chem. 2010 Oct;2(10):1529-46. doi: 10.4155/fmc.10.237.
Zotero 插件